Customer Acquisition Cost and Lifetime Value Analysis for Hong Kong IPOs

The Hong Kong Stock Exchange’s (HKEX) 2024 amendments to the Listing Rules, effective 1 January 2025, now mandate that applicants for a Main Board listing demonstrate “commercial viability” through a clear path to profitability, not just revenue growth. Rule 8.05(3) now requires a minimum market capitalisation of HKD 400 million and, for companies with a market cap below HKD 6 billion, a minimum revenue of HKD 400 million in the most recent financial year. This shift, coupled with the SFC’s heightened scrutiny of “pre-IPO” investments and marketing claims under the Code of Conduct for Persons Licensed by or Registered with the SFC (SFC Code, para. 17.1), forces sponsors and issuers to move beyond vanity metrics. For the 2025-2026 IPO pipeline, dominated by new economy and biotech firms, the ability to quantify and disclose unit economics — specifically Customer Acquisition Cost (CAC) and Lifetime Value (LTV) — has become a de facto requirement for a successful listing application. This article dissects how to structure and present CAC and LTV analysis in a Hong Kong IPO prospectus, using data from recent filings and regulatory guidance.

The Regulatory Imperative for Unit Economics Disclosure

The SFC and HKEX are no longer satisfied with top-line revenue growth unsupported by underlying profitability drivers. The 2025 Listing Rule amendments explicitly tie market capitalisation to revenue, but the real test lies in the sponsor’s ability to justify the sustainability of that revenue.

Sponsor Due Diligence Under the SFC Code

Paragraph 17.1 of the SFC Code requires sponsors to exercise “reasonable care” in verifying material facts in the prospectus. For a company with a high CAC relative to its peers, or a declining LTV, the sponsor must provide a reasoned explanation. Failure to do so exposes the sponsor to potential disciplinary action, as seen in the SFC’s 2023 reprimand of a sponsor for failing to challenge an issuer’s “optimistic” customer retention assumptions (SFC, 2023). The sponsor’s work programme must include a granular analysis of customer cohorts, churn rates, and the payback period for acquisition costs.

HKEX Guidance on “Commercial Viability”

HKEX’s Listing Decision HKEX-LD127-2024 (October 2024) clarified that a company with a high market capitalisation but negative gross profit and a CAC exceeding the average order value by 3x would likely fail the “commercial viability” test. The Exchange will examine the issuer’s ability to reduce CAC over time through brand recognition or network effects, and whether the LTV to CAC ratio (LTV:CAC) exceeds 3:1, the industry benchmark for sustainable growth. This is not a codified rule, but the Exchange’s discretionary power under Rule 8.04 to reject an application if the business is “not suitable for listing” is now being exercised with this framework in mind.

Methodology: Defining and Calculating CAC and LTV for a Hong Kong IPO

The prospectus must define these metrics precisely, with a clear audit trail. The definitions must be consistent with the issuer’s financial statements and the management discussion and analysis (MD&A) section.

Customer Acquisition Cost (CAC) — A Standardised Approach

CAC should be defined as the total sales and marketing expenses attributable to acquiring new customers in a given period, divided by the number of new customers acquired in that same period. The denominator must be “new paying customers,” not registered users or trial sign-ups. The numerator should include:

• Direct marketing costs (online advertising, trade shows, KOL fees).
• Sales team salaries, commissions, and bonuses.
• Allocated overhead (e.g., marketing software, office space for the sales team).

For a 2025-2026 IPO, the prospectus should present CAC for each of the three financial years presented in the track record period, ideally broken down by channel (e.g., online paid, organic, referral). A 2024 filing from a PRC-based SaaS company applying for a Main Board listing showed a CAC of HKD 4,200 per customer in FY2023, down from HKD 6,100 in FY2021, attributed to increased brand recognition and a shift to organic search.

Lifetime Value (LTV) — The Critical Assumption

LTV is the present value of the net profit attributable to a customer over the entire duration of the relationship. The calculation requires two key inputs: the average gross margin per customer per period, and the customer churn rate. The churn rate must be calculated on a cohort basis, not a simple period-over-period average, to avoid survivorship bias.

The prospectus must disclose the assumptions underpinning the LTV calculation, including the discount rate used. The SFC expects a discount rate that reflects the cost of capital of the issuer, not a generic market rate. For a pre-revenue biotech, the LTV calculation may be inapplicable; the Exchange will instead focus on the projected payback period for R&D expenditure. For a consumer platform, the LTV:CAC ratio is the primary metric. A ratio below 1.0 indicates the issuer is destroying value with each new customer.

Case Study: Applying the Framework to a Hypothetical 2025 IPO Applicant

Consider a Hong Kong-based fintech company, “PayFast Limited,” seeking a Main Board listing in 2025. Its prospectus must withstand regulatory scrutiny on its unit economics.

Revenue Model and Customer Acquisition

PayFast generates revenue from transaction fees (0.8% per transaction) and subscription fees (HKD 99 per month for merchants). Its CAC for FY2024 is HKD 2,800 per merchant, with an average monthly transaction volume of HKD 50,000 per merchant. The gross margin on transaction fees is 60%, and on subscriptions, 90%.

LTV Calculation and Cohort Analysis

Using a 24-month customer lifespan (based on a 4.2% monthly churn rate), the LTV per merchant is calculated as follows:

• Monthly gross profit from transactions: HKD 50,000 * 0.8% * 60% = HKD 240.
• Monthly gross profit from subscription: HKD 99 * 90% = HKD 89.10.
• Total monthly gross profit: HKD 329.10.
• LTV (24 months, discounted at 12% per annum): HKD 329.10 * [1-(1+0.01)^-24] / 0.01 = approximately HKD 6,980.

The LTV:CAC ratio is HKD 6,980 / HKD 2,800 = 2.49:1. This is below the 3:1 benchmark but above the 1:1 threshold. The sponsor would need to justify the path to a 3:1 ratio within 12-18 months post-listing, perhaps through reduced CAC from brand awareness or increased subscription uptake.

Regulatory Red Flags and Mitigants

The SFC would scrutinise the 4.2% monthly churn rate. If the churn rate is based on a cohort from 2022, but the company has since expanded to a new customer segment (e.g., large enterprises), the cohort data may be misleading. The sponsor must provide a sensitivity analysis showing the impact of a 1 percentage point increase in churn on LTV and the ratio. The prospectus must also disclose that the payback period for CAC is approximately 8.5 months (HKD 2,800 / HKD 329.10), which is acceptable for a growth-stage fintech.

Cross-Border and Sector-Specific Considerations

The analysis differs materially between a Hong Kong domiciled company and a PRC issuer using a VIE structure.

PRC VIE Issuers and the “User” Definition

For PRC internet platforms (e.g., e-commerce, social media) listed via a Cayman Islands holding company, the definition of “customer” is often blurred. The prospectus must distinguish between Monthly Active Users (MAUs) and paying customers. A 2023 prospectus for a PRC livestreaming platform listed its MAUs at 250 million, but its paying customers at only 8 million. The CAC per paying customer was HKD 45, but the LTV was only HKD 120, yielding a 2.67:1 ratio. The Exchange required a detailed breakdown of how MAU growth would convert to paying customers, and the associated marketing spend.

Biotech and Pre-Revenue Issuers

For biotech companies listing under Chapter 18C or 18A of the Main Board Listing Rules, CAC and LTV are not directly applicable. Instead, the focus is on the “cost per patient” in clinical trials and the projected “value per patient” based on licensing agreements. The HKEX’s Guidance Letter HKEX-GL112-22 (December 2022) requires a detailed breakdown of R&D expenditure by programme, and a sensitivity analysis on the probability of success. The “commercial viability” test is applied to the lead product candidate, not the entire pipeline.

Actionable Takeaways for Issuers and Sponsors

1. Prepare a cohort-based churn analysis for at least three years of the track record period, segmented by customer type and acquisition channel, to demonstrate the stability of the LTV calculation.
2. Set a target LTV:CAC ratio of at least 3:1 in the forecast period, and provide a clear, data-supported path to achieving it through reduced CAC or increased average revenue per user (ARPU).
3. Disclose the discount rate used in LTV calculations and justify it against the issuer’s weighted average cost of capital (WACC).
4. For PRC VIE issuers, explicitly define “paying customer” and reconcile it with MAU figures in the MD&A, avoiding any ambiguity.
5. Engage the sponsor’s internal valuation team early to stress-test the unit economics against the SFC’s expectations under the 2025 Listing Rule amendments, ensuring the prospectus narrative is consistent with the financial data.